Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $2.87B.
ENTERPRISE VALUE (EV)
$2.87B
Amylyx Pharmaceuticals, Inc.
Market Cap
$3.09B
Enterprise Value (EV)
$2.87B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.09B | $2.87B |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | $3.23B |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | $2.99B |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | $3.11B |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | $2.23B |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | $3.26B |
| AtriCure, Inc. (ATRC)vs › | $2.87B | $2.77B |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | $3.13B |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | $4.10B |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | $5.08B |
Market Cap
$3.09B
Total Debt
$4.70M
Cash
$226.65M
Enterprise Value
$2.87B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
